HSA
SUPN icon

Hussman Strategic Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Hussman Strategic Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-75,600
Closed -$2.19M – 269
2023
Q4 		$2.19M Sell
75,600
-18,000
-19% -$477K 0.5% 78
2023
Q3 		$2.58M Hold
93,600
– – 0.49% 76
2023
Q2 		$2.81M Buy
93,600
+600
+0.6% +$21K 0.52% 52
2023
Q1 		$3.37M Sell
93,000
-31,000
-25% -$1.19M 0.53% 56
2022
Q4 		$4.42M Hold
124,000
– – 0.72% 28
2022
Q3 		$4.2M Sell
124,000
-6,000
-5% -$195K 0.72% 27
2022
Q2 		$3.76M Buy
130,000
+26,000
+25% +$745K 0.65% 31
2022
Q1 		$3.36M Hold
104,000
– – 0.65% 38
2021
Q4 		$3.03M Buy
104,000
+11,000
+12% +$334K 0.67% 33
2021
Q3 		$2.48M Hold
93,000
– – 0.55% 52
2021
Q2 		$2.86M Sell
93,000
-51,000
-35% -$1.56M 0.59% 44
2021
Q1 		$3.77M Buy
144,000
+93,000
+182% +$2.6M 0.78% 14
2020
Q4 		$1.28M Buy
51,000
+36,000
+240% +$775K 0.34% 117
2020
Q3 		$313K Hold
15,000
– – 0.08% 239
2020
Q2 		$356K Hold
15,000
– – 0.09% 238
2020
Q1 		$270K Hold
15,000
– – 0.07% 249
2019
Q4 		$356K Sell
15,000
-10,000
-40% -$243K 0.11% 177
2019
Q3 		$687K Hold
25,000
– – 0.19% 153
2019
Q2 		$827K Sell
25,000
-15,000
-38% -$514K 0.23% 143
2019
Q1 		$1.4M Sell
40,000
-25,000
-38% -$930K 0.34% 123
2018
Q4 		$2.16M Buy
65,000
+15,000
+30% +$645K 0.52% 82
2018
Q3 		$2.52M Hold
50,000
– – 0.73% 54
2018
Q2 		$2.99M Hold
50,000
– – 0.81% 38
2018
Q1 		$2.29M Buy
+50,000
New +$2.09M 0.63% 77

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Hussman Strategic Advisors's SUPN Position: Q1 2024 in Review

Hussman Strategic Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2024, closing a stake of 75,600 shares — an estimated $2.19M sold.

Hussman Strategic Advisors first reported a position in SUPN in Q1 2018 and held it in 24 quarters. The position peaked at $4.42M in Q4 2022. 250 funds tracked by Wall St. Rank hold SUPN as of Q1 2024.

  • Hussman Strategic Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Hussman Strategic Advisors sold 75,600 Supernus Pharmaceuticals shares in Q1 2024, an estimated $2.19M.
  • Hussman Strategic Advisors first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 24 quarters.
  • Hussman Strategic Advisors's Supernus Pharmaceuticals position peaked at $4.42M in Q4 2022.
  • 250 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2024.

Based on Hussman Strategic Advisors's 13F filing for Q1 2024, filed 1 May 2024.